On Tuesday, Shares of Gilead Sciences, Inc. (NASDAQ:GILD), gained 2.78% to $104.90.
Gilead Sciences, declared that Paul Carter, Gilead’s Executive Vice President, Commercial Operations, will take part in a fireside chat at the Baird 2015 Healthcare Conference in New York on Wednesday, September 9 at 10:15 a.m. Eastern Time.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific.
Shares of Amgen, Inc. (NASDAQ:AMGN), inclined 5.13% to $154.56, during its last trading session.
Amgen, declared a neuroscience partnership with Novartis in the areas of Alzheimer’s disease and migraine. The partnership accelerates Amgen’s potential entry into Alzheimer’s disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer’s disease program directed at genetically predisposed individuals at risk of developing Alzheimer’s disease. The collaboration also enables Amgen to focus on the commercialization of its migraine programs in the U.S., Canada, and Japan, while leveraging Novartis’ strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.
The agreement combines each company’s BACE (beta-site APP-cleaving enzyme-1) programs targeting Alzheimer’s disease into a global co-commercialization and co-development arrangement. Novartis’ Phase 1/2a BACE inhibitor (CNP520) will be the lead molecule and each company’s pre-clinical BACE inhibitor programs will be potential follow-ons. Amgen will make upfront and milestone payments, and will be responsible for disproportional research and development (R&D) costs for an agreed-upon period followed by a 50/50 cost and profit share arrangement. CNP520 is planned to be comprised in a pioneering prevention study, in partnership with the Banner Alzheimer’s Institute. Amgen was the first company to clone the BACE gene and subsequent genetic validation of the BACE target has been confirmed by Amgen partner deCODE Genetics.
As part of the collaboration, Novartis receives global co-development rights and commercial rights outside of the U.S., Canada, and Japan to the investigative molecules in Amgen’s migraine portfolio program. This comprises AMG 334 in Phase 3 and AMG 301 in Phase 1, in addition to an option to commercialize an additional early-stage Amgen molecule in these territories. In exchange for territory rights, Novartis will fund disproportional amounts of global R&D expenses for an agreed-upon period on the migraine programs and pay Amgen double-digit royalties on sales.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
Finally, SanDisk Corporation (NASDAQ:SNDK), ended its last trade with 5.70% gain, and closed at $55.85.
SanDisk Corporation declared that John Scaramuzzo, senior vice president and general manager, Enterprise Storage Solutions, would address the investment community attending the 2015 Citi Global Technology Conference on Wednesday, September 9 at 11:00 a.m. ET.
SanDisk Corporation designs, develops, manufactures, and markets data storage solutions in the United States and internationally. The company offers removable cards, which are used in various applications and consumer devices, counting digital cameras, camcorders, smartphones, tablets, and eReaders under the SanDisk Ultra, SanDisk Extreme, and SanDisk Extreme PRO brands; and embedded products that are used in mobile phones, tablets, notebooks, and other portable and wearable devices, in addition to in automotive and connected home applications under the brand name iNAND.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
